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Designing clinical trials to study treatments for rare diseases is challenging
because of the limited number of available patients. A suggested design is known
as the small n sequential multiple assignment randomized trial (snSMART),
in which patients are first randomized to one of multiple treatments (stage 1).
Patients who respond to their initial treatment continue the same treatment for
another stage, while those who fail to respond are rerandomized to one of the
remaining treatments (stage 2). The data from both stages are used to compare
the efficacy between treatments. Analysis approaches for snSMARTs are limited,
and we propose a Bayesian approach that allows for borrowing of information
across both stages. Through simulation, we compare the bias, root-mean-square
error, width, and coverage rate of 95% confidence/credible interval of estimators
from of our approach to estimators produced from (i) standard approaches that
only use the data from stage 1, and (ii) a log-Poissonmodel using data from both
stages whose parameters are estimated via generalized estimating equations.We
demonstrate the root-mean-square error and width of 95% confidence/credible
intervals of our estimators are smaller than the other approaches in realistic
settings, so that the collection and use of stage 2 data in snSMARTs provide
improved inference for treatments of rare diseases.
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1 INTRODUCTION
The Orphan Drug Act defines rare diseases as disorders affecting fewer than 200 000 individuals in the United States.1
More than 8000 recognized rare diseases affect almost 30million individuals and their families in theUnited States.2 Iden-
tifying optimal treatment options for patients living with rare diseases is challenging due to the low number of individuals
affected. Randomized clinical trials (RCTs) are generally regarded as providing the strongest scientific evidence for the
efficacy of a treatment. Randomized clinical trials attempt to minimize bias and balance confounders across treatments
by employing randomization.3 However, confirmatory RCTs often require a large number of subjects, which is difficult
to attain in rare disease trials. Thus, RCTs studying treatment for rare diseases commonly have reduced power compared
with studies of nonrare diseases. As a result, rare disease trials are more likely to be single arm (63.0% versus 29.6% for
nonrare disease trials) and nonrandomized (64.5% versus 36.1% for nonrare disease trials).4 Small sample trials of rare
diseases that are randomized and multiarm are most likely crossover, n-of-1, or adaptive designs.5
There are disadvantages of the trial designs currently used in the rare disease landscape. For example, single arm stud-
ies are employed when the objective of the trial is to obtain preliminary evidence of the treatment efficacy and to collect
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additional safety data. As a result, single arm trials are not generally used to confirm efficacy.6 In a crossover study,
all subjects receive all experimental treatments. By design, each subject is their own control so that confounding and
between-subject variance is reduced, leading to the need of fewer subjects than a parallel design. However, since all partic-
ipants receive all candidate treatments by crossover, the treatments may expose participants to additional toxicities than a
standard RCT or switch participants from an efficacious treatment to a nonefficacious treatment. These challenges have
inspired the design of alternative crossover trials so that recruitment might be enhanced by offering patients the ability
to switch treatment if they received no benefit from the first.7
An n-of-1 trial is conducted in a single participant with multiple crossover treatment assignments. In an n-of-1 trial, a
participant is their own control so that confounding is reduced and the data can suggest which treatment produces a sat-
isfactory outcome for the participant. However, an n-of-1 trial usually requires multiple crossover treatment assignments
to defend against the effect of treatment across time, measurement error, and error from the participant's condition dif-
fering across time. Themultiple crossover treatment assignments potentially prolong the duration of the trial, whichmay
be burdensome for the participant and requires a well-developed trial protocol to keep the participant engaged.
Adaptive designs allow for design parameters, such as the sample size, randomization fraction, population recruited,
or doses, to be altered during the trial after interim data evaluation.6 The adaptiveness may reduce the number of subjects
recruited to inferior treatment, increase efficiency, improve recruitment, and take advantage of accumulating data to
enable early stopping of the trial. Alternatively, an adaptive trial is often more complex to design and analyze than other
standard clinical trial designs and is susceptible to bias due to temporal drift in participant characteristics.
Although the aforementioned designs described may be useful to study treatments in rare diseases, many have called
for more innovative trial designs.5 An example of such a design was proposed by Honkanen et al.8 This design consists of
an initial randomized placebo-controlled stage, a randomized withdrawal stage for subjects who responded, and a third
randomized stage for placebo nonresponders who subsequently respond to treatment. As an alternative way for reran-
domizing subjects, we propose design and methodological improvements for a small n sequential multiple assignment
randomized trial, the snSMART.9
An snSMART is an application of a SMART design10-12 in small samples (eg, rare diseases). In sequential multiple
assignment randomized trials (SMARTs), and hence snSMARTs, patients may be sequentially randomized to treatments
where second-stage treatment depends on response to first-stage treatment. For example, in the ARAMIS (a randomized
multicenter study for isolated skin vasculitis trial) trial, a two-stage snSMART design to compare three active treatments
(Figure 1), patients are randomized equally to one of the treatment arms and followed for six months. The responders
continue the same treatment for another six months, while the nonresponders are rerandomized to one of the remaining
treatments for an additional six months. The outcome of interest is a binary indicator of response to treatment as defined
by a combination of participant and physician measures.
Although SMARTs and snSMARTs have similar designs, we have differentiated their names because each has a dis-
tinctly different inferential goal. In a SMART, often the goal is to identify effective treatment sequences or dynamic
treatment regimens that define a personalized treatment guideline for each patient that consists of a first-stage treatment,
followed by a second stage treatment.13,14 In contrast, the goal of an snSMART here is in finding one superior treatment
among several that would be used by itself to treat patients. Thus, in this paper, we are not interested in identifying
dynamic treatment regimens within an snSMART.
We also highlight that some existing designs allow for absorbing endpoints, at which point all patients are assigned to
a different treatment.7,15 In contrast, SMARTs and snSMARTs typically do not deal with absorbing endpoints because a
treatment is assigned at each stage sequentially depending on the observed outcome of response at the end of current
treatment stage in SMARTs and snSMARTs.
Compared with a traditional multistage design, such as a crossover design, the snSMART is attractive because it allows
participants who have a satisfactory outcome from their treatment to continue to receive that treatment and who do not
have a satisfactory outcome from the treatment to switch to another treatment. Hence, an snSMART design may help to
improve participant recuitment and retention. However, analytic methods for an snSMART are not fully established, so
that the efficiency gains of an snSMART design compared with other designs in rare disease research have not yet been
confirmed.
Our methods are motivated by the snSMART ARAMIS, the design of which mimics the SMART design in metastatic
renal cancer.16,17 ARAMIS (NCT02939573) is a multinational trial to evaluate different treatment options for patients
with skin vasculitis. Vasculitides are uncommon diseases, which can affect almost any organ; although, vasculitis fre-
quently involves the skin as an isolated process or as part of systemic vasculitis. Without high-quality studies to guide
the management of skin vasculitis, treatment decisions are made based on anecdotal experience and expert opinions.
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FIGURE 1 Study design of an snSMART. Patients are randomized (R) to one of the treatment arms, A, B or C equally (1:1:1) and followed
for six months. The responders continue the same treatment for another six months, while the non-responders are re-randomized to one of
the remaining treatments for an additional six months
This uncertainty is reflected in variation between providers, leading to patients being treated with agents of uncertain effi-
cacy and unknown relative merit. ARAMIS compares the efficacy of three of the most commonly used treatments for the
treatment of skin vasculitis, ie, colchicine, dapsone, and azathioprine (Figure 1). Eligible patients are randomized with
equal chance of receiving one of the three treatments under investigation for six months. Those who do not respond after
the first stage (ie, six months) are rerandomized equally between the other two treatments. Responders in stage 1 remain
on their treatment in stage 2. The outcome of interest is response to treatment at six months as defined by a combination
of participant and physician measures.
In Section 2,we present amethod to analyze data froman snSMARTby sharing information across stages to evaluate the
efficacy of each single treatment. The efficacy of a treatment is defined as the response rate at six months after initiating
that treatment. In Section 3, we present simulation studies to illustrate our model's properties under various scenarios.
Our paper concludes with a discussion in Section 4.
2 METHOD
The outcome of interest after each stage is a dichotomized variable, where 1 denotes response and 0 denotes nonresponse
to the assigned treatment. We propose a Bayesian approach that borrows information across both stages to estimate the
individual response rate of each treatment. The individual response rate we are interested in is a permanent feature of
treatment similar to the treatment effect in a large parallel group trial. Wemodel the first stage outcome as the probability
of having a response to the first stage treatment. The second stage outcome is modeled conditionally on the first stage
outcome linking the first and second stage response probabilities through linkage parameters.
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We compare the estimator of the response rate using the proposed method to estimators produced from three other
methods, ie, (i) a log-Poisson model using data from both stages whose parameters are estimated via generalized estimat-
ing equations, (ii) a Bayesian method using only the first stage data, and (iii) a maximum likelihood method (maximum
likelihood estimation) using only the first stage data. The details of our proposedmodel and the log-Poissonmodel will be
discussed next, and simulation results for the comparison of estimators produced from the four methods will be shown
in the Section 3.
2.1 Bayesian joint stage modeling
For each subject i = 1, … ,N, stage j = 1, 2, and treatment k = A,B, … K, where N denotes the total sample size and
K denotes the number of arms, let Yijk denote the observed response outcome. We model the first stage outcome and the
second stage outcome given the first stage outcome each as a Bernoulli random variable. The first stage response rate is
denoted as 𝜋k for treatment k. The second stage response rate for first stage responders is equal to 𝛽1𝜋k. For nonresponders
to treatment k in the first stage who receive treatment k′ in the second stage, the second stage response rate in the second
stage is equal to 𝛽0𝜋k′ . In practice, we assume (i) the linkage parameters (𝛽0, 𝛽1) do not depend on the initial treatment k.
(ii) The linkage parameter for nonresponders is smaller than 1, ie, 𝛽0 < 1. (iii) The linkage parameter for responders is
greater than 1, ie, 𝛽1 > 1. Via simulation, we examine the violations of the assumptions in Section 3.
Our proposed Bayesian joint stage model (BJSM) is as follows:
Yi1k|𝜋k∽Bernoulli(𝜋k)
Yi2k′ |Yi1k, 𝜋k∽Bernoulli ((𝛽1𝜋k)Yi1k (𝛽0𝜋k′ )1−Yi1k) .
Prior distributions on the first stage response rates and the linkage parameters are used to incorporate physician beliefs
about the treatments. For the ARAMIS trial, we specify priors for the parameters involved in the model 𝜋k∽Beta(𝜁k, 𝜂k),
𝛽0∽Beta(𝜁0, 𝜂0), 𝛽1∽Pareto(1, 𝜙). For 𝜋k, we have chosen to use the hyperparameter values 𝜁k = 0.4 and 𝜂k = 1.6 for two
reasons. First, these parameters lead to a prior mean of 𝜁k∕(𝜁k + 𝜂k) = 0.2 for each of the arms, which was a reasonable
a priori setting for the ARAMIS study. Second, the sum of the two parameters of a Beta distribution can be viewed as a
prior sample size because the prior variance is inversely proportional to that sum. Thus, we assume our prior information
is based upon a sample size of 𝜁k + 𝜂k = 2 patients. For 𝛽0, we have chosen hyperparameter values 𝜁0 = 1 and 𝜂0 = 1,
which lead to a uniform distribution over the interval [0, 1]. For 𝛽1, we have assumed a hyperparameter value of 𝜙 = 3,
so that, on average, the second stage response rate is 𝜙∕(𝜙 − 1) = 1.5 times as large as the first stage response rate.
2.2 Log-Poisson joint stage modeling
The log-Poisson joint stage model, which we refer to LPJSM, is a frequentist way of modeling data from two stages, where
we use a log link to model the mean and the Poisson family to model the variance of the outcome. We model the the log
of each response rate instead of the logit of each response rate mainly for interpretability. The model is as follows:
log (E(Yi1k)) = log(𝜇i1k) = 𝛼A1{k = A} + 𝛼B1{k = B} + 𝛼C1{k = C} (1)
log (E(Yi2k′ )) = log(𝜇i2k′ ) = 𝛼A1{k′ = A} + 𝛼B1{k′ = B} + 𝛼C1{k′ = C} + 𝛾1Yi1k + 𝛾0(1 − Yi1k), (2)
where 1{·} is an indicator function. The response rates 𝜋k and the linkage parameters 𝛽1 and 𝛽0 from the BJSM are
equivalent to the exponentiated values of 𝛼k, 𝛾1, and 𝛾0, respectively.





V−1i (Y i − 𝝁i) = 0, (3)
where Y i = (Yi1k,Yi2k′ )T , 𝝁i = (𝜇i1k;𝜇i2k′ )T , 𝜽 is the parameter vector with 𝜽 = (𝛼A, 𝛼B, 𝛼C, 𝛾1, 𝛾0)T, and Vi is the working
covariance matrix of Yi with V i = A1∕2i R(𝛼)A
1∕2
i ,
19 where A1∕2i is a diagonal matrix with elements being the square root of
Var(Yi jk), the variance of the outcome of the ith patient at the jth stage under treatment k. The variance of the outcome
of the ith patient at the jth stage is modeled with a Poisson family variance structure, Var(Yi jk) = 𝜇i jk. We use the
Poisson family variance structure to construct Vi in Equation (3) to find the estimator of 𝜽 as opposed to the binomial
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family variance structure because others have reported that estimation sometimes fails to converge when attempting to
fit log-binomial models with a small sample size.20 In addition, we use an independence working correlation structure
R(𝛼) = I2× 2 in the estimating equation because the independence working correlation structure is recommended when
binary responses have less than binomial variation over clusters.21

















. We use the binomial family variance structure,
Var(Yi jk) = 𝜇i jk(1 − 𝜇i jk), to construct Vi in Σ0 and Σ1 to estimate variance of ?̂? because the “sandwich” estimator is
consistent, when Vi is correctly specified and even if R(𝛼)misspecified.22
3 SIMULATIONS
We set up the scenarios for our simulation studies in two sections, ie, simulations when the assumptions for BJSM are sat-
isfied and simulationswhen our assumptions are violated.We compare the bias, root-mean-square error (rMSE), coverage
rate, andwidth of the 95% credible/confidence interval (CI) of the estimated parameters.When the BJSM assumptions are
true, we compare the estimators from our proposed method (BJSM) to estimators produced from other three methods, ie,
the LPJSM, described in Section 2.2, Bayesian first stage model (BFSM), and a first stage maximum likelihood estimates
(FSMLEs). For both the BFSM and FSMLE, we only use the first stage data for estimation, and for the BFSM, we assume
the same prior distribution for 𝜋k as the BJSM.When assumptions are violated, we compare the BJSM to an extensionwith
multiple linkage parameters (BJSMM) and the LPJSM. The BJSMM is the same as that of the BJSM except that we allow
the linkage parameters to depend on the initial treatment, ie, 𝛽0 is now replaced by 𝛽0k and 𝛽1 is now replaced by 𝛽1k. We
use exactly the same values for the hyperparameters as the BJSM for the prior densities of the BJSMM so that we allow
for estimating 𝛽0k and 𝛽1k values that differ among different treatments k, but we give each the same prior distribution.
Bias is defined as the average of the differences between the true value of 𝜋k and the estimated 𝜋k in all simulations. The
rMSE is calculated by taking the square root of the mean-square error of the estimators in all simulations. The simulated
coverage rate is the frequency that the true value of the response paramter falls in the 95% CI for all simulations. The 95%
CIs for the BJSM, BFSM, and BJSMM are the highest posterior density CIs, which is the narrowest interval that covers
the 95% of the posterior distribution of 𝜋k. The 95% CIs for the LPJSM and FSMLE are derived based on the asymptotic
normality of the estimator of 𝜋k in these two methods and calculated by the estimator plus or minus 1.96 times of the
standard error of the estimator. The parameters are estimated via the R function jags and gee in the R package rjags and
gee, respectively. The computer programs used to derive estimates and CIs are available upon request from the primary
author.
3.1 Simulation scenarios
We simulate 2000 realizations per scenario; each scenario is a three-arm snSMART. The true values of the response rates
in each arm and the linkage parameters in each stage vary in different scenarios; details are presented in Table 1.We focus
on simulation results where the total snSMART sample size is 90 (30 patients per treatment), but we provide results for
total sample sizes of 45 and 180 in Section 6.
Scenarios 1 to 3 represent three ideal settings. In these scenarios, the linkage parameters for nonresponders and for
responders are the same for all three treatments, which means the model specification is the same as the data generating
process. In scenarios 4 to 12, we vary the values of the linkage parameters to investigate model properties when assump-
tions are violated (the assumptions are enumerated in Section 2.1). Assumption (i) is violated in scenarios 4 to 7 and 10
to 12. Assumption (ii) is violated in scenarios 8, 10, and 12, and assumption (iii) is violated in scenarios 9, 11, and 12.
3.2 Simulation results when the BJSM assumptions are true
For scenarios 1 to 3, the bias and rMSE for estimators of the response rates are shown in Table 2. The response rate
estimators of the BJSM have the smallest rMSEs among all four methods. The rMSEs of the estimators from the BJSM
and LPJSM are smaller than the rMSEs provided by the BFSM and FSMLE, which only use data from the first stage.
In scenario 2, the BJSM provides the estimators with smallest bias compared with other three methods. In scenarios
1 and 3, the bias of the estimators for the BJSM is still small but slightly higher than the bias for the other three methods.
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TABLE 1 Simulation scenarios. 𝜋k is the response rate at six months for the treatment
k = A,B,C. 𝛽0k is the linkage parameter for the first stage nonresponders treated with treatment k.
𝛽1k is the linkage parameter for the first stage responders treated with treatment k. The linkage
parameters link the second stage response rates with the first stage response rate in our proposed
model. The three assumptions are (i) the linkage parameters do not depend on the initial treatment
k, ie, 𝛽1k = 𝛽1 and 𝛽0k = 𝛽0. (ii) The linkage parameter for nonresponders is smaller than 1, ie,
𝛽0 < 1. (iii) The linkage parameter for responders is greater than 1, ie, 𝛽1 > 1
Scenarios 𝝅A 𝝅B 𝝅C 𝜷0A 𝜷0B 𝜷0C 𝜷1A 𝜷1B 𝜷1C Assumptions Violated
1 0.3 0.3 0.3 0.8 0.8 0.8 1.5 1.5 1.5 none
2 0.2 0.3 0.4 0.6 0.6 0.6 1.5 1.5 1.5 none
3 0.2 0.3 0.4 0.8 0.8 0.8 1.5 1.5 1.5 none
4 0.2 0.3 0.4 0.3 0.6 0.9 1.5 1.5 1.5 (i)
5 0.2 0.3 0.4 0.6 0.6 0.6 1.2 1.5 1.8 (i)
6 0.2 0.3 0.4 0.3 0.6 0.9 1.2 1.5 1.8 (i)
7 0.2 0.3 0.4 0.9 0.6 0.3 1.2 1.5 1.8 (i)
8 0.2 0.3 0.4 1.2 1.2 1.2 1.5 1.5 1.5 (ii)
9 0.2 0.3 0.4 0.6 0.6 0.6 0.8 0.8 0.8 (iii)
10 0.2 0.3 0.4 0.3 0.6 1.2 1.2 1.5 1.8 (i), (ii)
11 0.2 0.3 0.4 1.2 1.2 1.2 0.8 0.8 0.8 (ii), (iii)
12 0.2 0.3 0.4 0.3 0.6 1.2 0.8 1.5 1.8 (i), (ii), (iii)
TABLE 2 Simulated bias and root-mean-square error (rMSE) for the estimators of 𝜋k
where the Bayesian joint stage modeling (BJSM) assumptions are satisfied. Four modeling
approaches, ie, BJSM, log-Poisson joint stage modeling (LPJSM), Bayesian first stage modeling
(BFSM), and first stage maximum likelihood estimation (FSMLE) are compared. The sample
size per treatment arm is 30. 𝜋k is the response rate at six months for treatment k, k = A,B,C
BJSM LPJSM BFSM FSMLE
Scenario Bias rMSE Bias rMSE Bias rMSE Bias rMSE
1 𝜋A 0.008 0.062 -0.001 0.069 -0.008 0.079 -0.002 0.084
𝜋B 0.008 0.062 0.002 0.069 -0.006 0.078 0.001 0.083
𝜋C 0.008 0.061 -0.002 0.068 -0.008 0.078 -0.001 0.083
2 𝜋A -0.001 0.056 -0.001 0.059 -0.002 0.069 -0.002 0.074
𝜋B 0.001 0.063 0.000 0.070 -0.006 0.078 0.001 0.083
𝜋C 0.000 0.067 0.002 0.077 -0.014 0.085 -0.002 0.089
3 𝜋A 0.005 0.056 -0.001 0.057 -0.002 0.069 -0.002 0.074
𝜋B 0.008 0.062 0.000 0.069 -0.006 0.078 0.001 0.083
𝜋C 0.011 0.064 0.002 0.076 -0.014 0.085 -0.002 0.089
This may be because the prior mean for the linkage parameter for nonresponders is 0.5, which is closer to 0.6, the setting
in scenario 2, than 0.8, the setting in scenarios 1 and 3. These observations suggest that, in settings where the assumptions
are satisfied, jointly modeling data from two stages provides improved estimators for treatment due to smaller rMSEs. In
particular, the biggest gain in rMSE is given by the BJSM, which also produces small to negligible bias. Table 3 presents
the 95% CI width and coverage rates. Here, we see the average width of the 95% CI of the BJSM is smaller than the other
approaches, and the coverage rate is around the target 95%.
3.3 Simulation results when the BJSM assumptions are violated
Simulation results when the assumptions for the BJSM are violated are shown in Tables 4 and 5. When only assumption
(i) is violated (scenarios 4 to 7), we see that the bias for the response rate estimators is small for all three methods. The
estimators of the BJSMM has the smallest bias in scenarios 4 to 6 and BJSM has the smallest bias in scenario 7. The
estimators of the BJSM and BJSMMhave smaller rMSEs than the LPJSM approach.When only assumption (ii) is violated,
as in scenario 8, we see that the response rates are overestimated for all treatment arms by the BJSM and BJSMM.
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TABLE 3 Simulated width and coverage of 95% CI for the estimators of 𝜋k where the Bayesian
joint stage modeling (BJSM) assumptions are satisfied. Four modeling approaches, ie, BJSM,
log-Poisson joint stage modeling (LPJSM), Bayesian first stage modeling (BFSM), and first stage
maximum likelihood estimation (FSMLE) are compared. The sample size per treatment arm is 30.
𝜋k is the true response rate at six months for the treatment k, k = A,B,C. CR=Coverage Rate
BJSM LPJSM BFSM FSMLE
Scenario Width CR Width CR Width CR Width CR
1 𝜋A 0.240 0.944 0.265 0.931 0.299 0.903 0.321 0.950
𝜋B 0.240 0.948 0.266 0.936 0.300 0.908 0.322 0.949
𝜋C 0.240 0.944 0.265 0.934 0.299 0.908 0.321 0.950
2 𝜋A 0.213 0.929 0.228 0.932 0.256 0.945 0.277 0.945
𝜋B 0.245 0.940 0.269 0.936 0.300 0.908 0.322 0.949
𝜋C 0.265 0.948 0.305 0.937 0.323 0.930 0.344 0.930
3 𝜋A 0.210 0.936 0.222 0.936 0.256 0.945 0.277 0.945
𝜋B 0.240 0.942 0.263 0.936 0.300 0.908 0.322 0.949
𝜋C 0.258 0.956 0.300 0.937 0.323 0.930 0.344 0.930
TABLE 4 Simulated bias and root-mean-square error (rMSE) for the
estimators of 𝜋k when assumptions are violated. Three modeling approaches,
ie, Bayesian joint stage modeling (BJSM), BJSM to an extension with
multiple linkage parameters (BJSMM), and log-Poisson joint stage modeling
(LPJSM) are compared. The sample size per treatment arm is 30. 𝜋k is the
response rate at six months for treatment k, k = A,B,C
BJSM BJSMM LPJSM
Scenario Bias rMSE Bias rMSE Bias rMSE
4 𝜋A -0.024 0.060 -0.021 0.059 -0.029 0.064
𝜋B -0.004 0.063 -0.001 0.062 -0.007 0.070
𝜋C 0.027 0.068 0.032 0.071 0.037 0.086
5 𝜋A -0.010 0.054 -0.005 0.055 -0.011 0.056
𝜋B -0.003 0.062 0.003 0.063 -0.005 0.068
𝜋C 0.022 0.072 0.017 0.070 0.017 0.080
6 𝜋A -0.033 0.061 -0.027 0.060 -0.038 0.066
𝜋B -0.008 0.062 0.000 0.062 -0.012 0.069
𝜋C 0.048 0.080 0.048 0.081 0.050 0.093
7 𝜋A 0.014 0.055 0.017 0.058 0.017 0.059
𝜋B 0.001 0.062 0.007 0.063 0.001 0.069
𝜋C -0.004 0.073 -0.013 0.073 -0.018 0.080
8 𝜋A 0.023 0.060 0.029 0.063 -0.001 0.054
𝜋B 0.036 0.069 0.042 0.073 0.000 0.065
𝜋C 0.047 0.076 0.054 0.081 0.001 0.073
9 𝜋A -0.015 0.054 -0.016 0.054 -0.001 0.061
𝜋B -0.029 0.064 -0.030 0.063 0.000 0.073
𝜋C -0.047 0.075 -0.047 0.075 0.002 0.081
10 𝜋A -0.038 0.063 -0.030 0.060 -0.045 0.069
𝜋B -0.015 0.063 -0.005 0.062 -0.024 0.070
𝜋C 0.073 0.095 0.078 0.099 0.071 0.105
11 𝜋A 0.011 0.053 0.014 0.054 0.000 0.056
𝜋B 0.010 0.055 0.013 0.056 0.000 0.067
𝜋C 0.006 0.055 0.010 0.055 0.001 0.076
12 𝜋A -0.047 0.066 -0.039 0.063 -0.053 0.073
𝜋B -0.014 0.063 -0.005 0.062 -0.022 0.070
𝜋C 0.075 0.097 0.078 0.099 0.076 0.109
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TABLE 5 Simulated width and coverage of 95% CI for the estimators of 𝜋k when
assumptions are violated. Three modeling approaches: Bayesian joint stage modeling
(BJSM), BJSM with multiple linkage parameters (BJSMM), and log-Poisson joint stage
modeling (LPJSM) are compared. The sample size per treatment arm is 30. 𝜋k is the true
response rate at six months for the treatment k, k = A,B,C. CR=Coverage Rate
BJSM BJSMM LPJSM
Scenario Width CR Width CR Width CR
4 𝜋A 0.200 0.868 0.206 0.890 0.220 0.854
𝜋B 0.240 0.933 0.247 0.948 0.266 0.929
𝜋C 0.262 0.950 0.264 0.938 0.303 0.931
5 𝜋A 0.208 0.932 0.213 0.936 0.215 0.915
𝜋B 0.243 0.942 0.250 0.950 0.262 0.930
𝜋C 0.270 0.942 0.278 0.951 0.311 0.942
6 𝜋A 0.194 0.854 0.203 0.880 0.207 0.824
𝜋B 0.238 0.936 0.248 0.946 0.259 0.923
𝜋C 0.266 0.912 0.271 0.912 0.310 0.917
7 𝜋A 0.220 0.957 0.223 0.949 0.222 0.948
𝜋B 0.247 0.948 0.253 0.950 0.264 0.936
𝜋C 0.272 0.928 0.284 0.935 0.313 0.930
8 𝜋A 0.211 0.926 0.219 0.927 0.210 0.930
𝜋B 0.235 0.922 0.245 0.922 0.252 0.938
𝜋C 0.246 0.899 0.255 0.882 0.291 0.944
9 𝜋A 0.206 0.926 0.207 0.933 0.238 0.934
𝜋B 0.235 0.916 0.236 0.918 0.282 0.927
𝜋C 0.250 0.892 0.251 0.900 0.316 0.932
10 𝜋A 0.188 0.834 0.199 0.868 0.202 0.787
𝜋B 0.232 0.922 0.244 0.942 0.255 0.902
𝜋C 0.260 0.825 0.264 0.811 0.308 0.876
11 𝜋A 0.207 0.949 0.212 0.950 0.217 0.928
𝜋B 0.230 0.960 0.235 0.968 0.260 0.932
𝜋C 0.238 0.972 0.243 0.974 0.298 0.944
12 𝜋A 0.183 0.792 0.194 0.838 0.192 0.735
𝜋B 0.232 0.925 0.244 0.942 0.258 0.907
𝜋C 0.259 0.814 0.264 0.810 0.312 0.863
The response rates are overestimated to balance the effect of the underestimated 𝛽0 on the stage 2 response rates of nonre-
sponders. The bias for the estimators is higher for BJSM and BJSMM but still small. The estimators from the LPJSM have
the smallest bias and rMSEs.When only assumption (iii) is violated as in scenario 9, the response rates are underestimated
for all arms by the BJSM and BJSMM. The response rates are underestimated to balance the effect of the overestimated 𝛽1
on the stage 2 response rates of responders. The estimators from the LPJSM have smallest bias but the rMSEs are higher
compared with those from the BJSM and BJSMM.
When more than one assumption is violated (scenarios 10-12), the bias for the estimators of the response rates is lower
in scenario 11, where assumption (i) holds and assumptions (ii) and (iii) are violated. This finding occurs because when
assumption (ii) is violated, the BJSM and BJSMM tend to overestimate the response rates, and when assumption (iii) is
violated, the BJSM and BJSMM tend to underestimate the response rates. and when both assumptions (ii) and (iii) are
violated, two errors cancel each other. The BJSM and BJSMM have smaller rMSEs in all three scenarios.
In general, when the assumptions are violated, the response rate estimators of the BJSM have smaller bias and rMSEs
than the LPJSM inmost of the settings, and smaller rMSEs than the standard approaches that only use the data in stage 1.
When multiple linkage parameters are considered in the BJSMM, we do not see a large reduction of bias or rMSEs.
In Table 5, we can see the average width of the 95% CI of the BJSM is smaller than the other approaches. When only
assumption (i) is violated (scenarios 4 to 7), the coverage rates of 95% CIs for treatments B and C are around the target
95%. The coverage rate is readily below the target for all three approaches in scenarios 4 and 6. When only assumption
(ii) (scenario 8) or assumption (iii) is violated (scenario 9), the coverage rate for the treatment C is below the target.
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This can be explained by the larger bias in the response rate estimator for treatment C in scenarios 8 and 9. In scenario 10,
(when assumption (i) and (ii) are violated), and scenario 12, when all the assumptions are violated, the coverage rates of
95% CIs are below the target 95% for treatment A and C because the response rate estimators have higher bias compared
with the estimators of the treatment B. When assumptions (ii) and (iii) are violated at the same time, the coverage rates
are greater than the target 95% for the BJSM and BJSMM and below the target 95% for the LPJSM. Similar trends were
observed for sample sizes of n= 45 and 180; details are given in Tables 6-13 in Supporting Information.
4 DISCUSSION
In this manuscript, we have presented a Bayesian method (BJSM) to estimate the response rates of multiple treatments
from snSMART with two stages. The BJSM is a novel method that links the response rates from two stages of one clinical
trial via linkage parameters. The BJSM provides accurate estimators and straightforward clinical interpretations for the
parameters. We compared the proposed method to three other methods via simulation and found that the BJSM provides
the most accurate estimators among all four methods in small samples.
The BJSM relies on three key assumptions as outlined in Section 2.1. These assumptions simplify our model and make
our model easier to interpret. However, there might be situations where the assumptions are violated. Simulation results
suggest that the BJSM is able to estimate treatment arm response rates with small sample sizes even when the linkage
parameters actually vary among the treatment arms. Nonetheless, further research is certainly warranted to determine
the sample size at which moving from a BJSM to a BJSMMmight be warranted.
Assumptions (ii) and (iii) in Section 2.1 that constrain the values of the linkage parameters generally hold when the
response rates are similar and low (ie, less than 50%) for all treatments in the trial. For many rare diseases, these assump-
tions are realistic, and thus, violations generally do not pose problems. If the assumptions are violated, the BJSM provides
more biased estimates than the LPJSM but is more efficient. Sensitivity analyses using the LPJSM can always be done to
compare results for the two methods.
A limitation that develops fromour assumptions and corresponding priors is that the posterior distributions of 𝛽1 and 𝜋k
can have positive probability for 𝛽1𝜋k > 1. In reality, we can not have a response rate greater than 1, but ourmodels allow
for this. To circumvent this potential problem,we considered a powermodel formulation of the BJSM. In the powermodel
formulation, the second stage response rates are defined as 𝜋𝛽0k′ and 𝜋
𝛽1
k for nonresponders and responders, respectively.
This allows 𝛽0 and 𝛽1 to vary on the positive real line. Ultimately, we decided against the power formulation as the linkage
parameters are not clinically interpretable and our simulations for the proposed version of BJSMdid not draw any samples
such that 𝛽1𝜋k > 1, making it unlikely for this limitation to be a problem in practice in similar settings.
For ARAMIS, the binary six-month response is based on an objective measure (number of new lesions) that is further
combined with two subjective measures, one from the physician and one from the patient. Thus, it seemed reasonable
to collapse this complex set of outcomes into a single binary outcome of response. If ARAMIS had instead had a sin-
gle objective continuous measure of efficacy, analysis of a dichotomized endpoint would have been unwise, due to the
loss of information that dichotomization creates. We also emphasize that ARAMIS assumes no carry-over effects and no
period effects. If carry-over effects and/or period effects exist in other applications, our proposed model would need to be
modified.
Future work includes extending the BJSM to nonbinary outcomes (ie, continuous and survival outcomes) and estab-
lishing sample size calculations based on the analysis of snSMARTs using the BJSM. We aim to develop sample size
calculations and an easy-to-use corresponding applet that can target specific differences between treatment arms. The
sample size calculations will lead us to consider alternative designs of snSMARTs where more than three treatments are
involved or there is an imbalance in second stage randomization. We are also working on another paper in which we
extend our BJSM to estimate the treatment effects of dynamic treatment regimens.
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